Introduction {#Sec1}
============

Lowering the low-density lipoprotein (LDL-C) and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) \[[@CR1]\] ratio is associated with significant reduction in coronary atherosclerotic morbidity and mortality rates \[[@CR2], [@CR3]\]. Studies have found myalgia and muscle cramps reported by 10.5--60 % of patients treated with statins \[[@CR4], [@CR5]\]. In clinical practice, patient concerns over cost and adverse effects must be addressed and at times negotiated to achieve a therapeutic goal. During any 2-year period, between 25.4 and 40.1 % of patients may become non-adherent to a daily statin regimen \[[@CR6]\]. Periodic dosing of rosuvastatin or atorvastatin has been described in previous studies \[[@CR7]--[@CR9]\] given their long physiologic half-life and a plasma half-life seven times greater than simvastatin. We examine the process of periodic dosing of rosuvastatin or atorvastatin to reach therapeutic goals and promote patient adherence over an 8-year period.

Methods {#Sec2}
=======

In 2002, several patients in a private internal medicine practice, who had failed to improve their lipid profile with non-pharmacologic options, had stopped simvastatin treatment because of myalgias. These patients were given the option to try periodic statin therapy to achieve a TC/HDL-C ratio less than 5. Over the next 6 months, a selection process was standardized and offered to other patients who stopped taking their statin because of myalgias or cost. Patients who were adherent to their prescribed statin treatment were excluded. During a 7-month review of medication profiles, 46 patients (Table [1](#Tab1){ref-type="table"}) were identified who had chosen a non-daily dosing schedule during an 8-year period since 2002. Each patient was given 14 tablets: 20 patients were given rosuvastatin 5 mg tablets, 24 were given 10 mg tablets of atorvastatin, and 2 patients were unable to tolerate any dose. Instructions for the first week were to take one tablet on Monday and a second tablet on Wednesday. They were then to take a tablet on Monday, Wednesday, and Friday for the next 4 weeks, and follow-up in the office with a lipid profile. During the office visit, post-treatment activity and lifestyle concerns were addressed, as well as the results of the lipid profile. Following a discussion with the patient about the lipid profile results and their perceptions of either the 30 mg weekly dose of atorvastatin or 15 mg of rosuvastatin; each patient was given the choice of maintaining the therapy, doubling the mg dose, or increasing the frequency up to 5 days per week. The initial post-treatment interview and lipid profile directed that a prescription should be given for 30 additional tablets of the negotiated dose to "take as directed." Subsequent lipid testing was performed at 3- to 6-month intervals until the TC/HDL-C goal of less than 5 was achieved. Stepwise dosing was titrated down if myalgias arose or as per patient request. The primary endpoint in a retrospective chart review was to assess the concentration of LDL-C and the TC/HDL-C ratio with patient-selected atorvastatin and rosuvastatin dosing intervals. The secondary endpoint was a head-to-head comparison of the lipid reductions with atorvastatin versus rosuvastatin. Statistical analyses to compare pre-treatment and post-treatment LDL-C level and TC/HDL-C ratio in the whole group were performed using a paired-samples *t-*test. An independent samples *t-*test was conducted to compare pre- and post-treatment LDL-C level and TC/HDL-C ratio reduction in the rosuvastatin verses atorvastatin groups. Results were expressed as means and 95 % confidence intervals (CIs). A *P* value of less than 0.05 was considered statistically significant. All data were processed and analyzed using SPSS, version 21 (IBM Inc., Armonk, NY, USA). An institutional review board approved the ethics of this study.Table 1Patient characteristicsAll (*N* = 44)Atorvastatin (*N* = 24)Rosuvastatin (*N* = 20)Age, years69 (10.6)71 (10.3)66 (10.6)Female (%)31.850.050.0Male (%)68.256.743.3Pre-treatment LDL143 (38.5)138 (43)149 (32)Pre-treatment CH/HDL5.4 (1.3)5.2 (1.3)5.6 (1.3)Doses per month14.9 (3.5)14.7 (3.6)15.1 (3.6)Months of treatment36.936.537.3Data are presented as mean (SD) unless otherwise indicated*CH* cholesterol, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *SD* standard deviation
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The patients ranged from 46 to 79 years of age and were treated for a mean duration of 37 months (range 2--99) with titration of atorvastatin from 10 to 40 mg and rosuvastatin from 5 to 20 mg. Two patients (4.3 %) failed to tolerate any dose of statin, and three patients (6.5 %) decided to take their medication no more than twice weekly (which was not related to myalgias). Of the 44 patients treated with either rosuvastatin or atorvastatin, there was a statistically significant decrease from baseline in the mean LDL-C level of 43.3 mg/dL (30.2 %) (95 % CI 34--52.6, *P* \< 0.0001) (Fig. [1](#Fig1){ref-type="fig"}, left). In the atorvastatin group, the target TC/HDL-C ratio was achieved in two patients (8.3 %) with 2-days/week therapy, in eight patients (33.3 %) with 3-days/week therapy, in ten patients (41.7 %) with therapy every other day, and in four patients (16.7 %) with 5-days/week therapy. In the rosuvastatin group, the target TC/HDL-C ratio was achieved in one patient (5 %) with 2-days/week therapy, in eight patients (40 %) with 3-days/week therapy, in seven patients (35 %) with therapy every other day, and in four patients (20 %) with 5-days/week therapy. There was also a statistically significant decrease from pre-treatment levels in the mean TC/HDL-C ratio of 1.72 (31.1 %) (95 % CI 1.4--2, *P* \< 0.0001) (Fig. [1](#Fig1){ref-type="fig"}, right). In terms of total weekly dose of these two statins, 50 % of the patients were controlled with 17.5--30 mg per week of rosuvastatin or with 20--50 mg per week of atorvastatin (Fig. [2](#Fig2){ref-type="fig"}). The maximum weekly dose of 100 mg or more was needed in 5 % of the rosuvastatin group and in 12.5 % of the atorvastatin group. The head-to-head comparison failed to show a statistically significant difference between rosuvastatin and atorvastatin in the reduction in mean LDL-C concentration. Rosuvastatin produced a 33.9 % reduction compared with a 26.8 % reduction with atorvastatin, with a mean difference in absolute LDL-C reduction of 13.62 mg/dL between groups (95 % CI −4.8--32, *P* = 0.143) (Fig. [3](#Fig3){ref-type="fig"}, left). Reduction of the mean TC/HDL-C ratio with rosuvastatin was 32.9 % compared with a 30.8 % reduction with atorvastatin. The mean difference in TC/HDL-C ratio reduction of 0.27 between both groups was not statistically significant 95 % CI −0.9--0.4, *P* = 0.399) (Fig. [3](#Fig3){ref-type="fig"}, right).Fig. 1Comparison of pre- and post-treatment LDL-C level (*left*) and TC /HDL ratio (*right*) in the 44 patients. *HDL* high-density lipoprotein, *LDL-C* low-density lipoprotein cholesterol, *TC* total cholesterolFig. 2Weekly cumulative dose of rosuvastatin or atorvastatinFig. 3Head-to-head comparison of LDL-C level (*left*) and TC/HDL ratio (*right*) reduction in the atorvastatin and rosuvastatin group. *HDL* high-density lipoprotein, *LDL-C* low-density lipoprotein cholesterol, *TC* total cholesterol
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The clinical impact of long-term statin use may be compromised by patient concerns, including myalgias and cost, resulting in decreased adherence. This study demonstrates that periodic dosing of rosuvastatin or atorvastatin is effective in achieving a desirable LDL-C and TC/HDL-C ratio for up to 8 years. Rosuvastatin and atorvastatin were selected because of their uniquely long in vivo activity. The half-life of atorvastatin is approximately 14 h, and the half-life of its HMG-CoA reductase inhibiting metabolites approaches 20--30 h. Rosuvastatin has an extended half-life of 19 h as well as enterohepatic recirculation in most patients \[[@CR10]\]. The slow hepatic metabolism of 5--50 % of the drug has been shown to occur over 3 days in in vitro studies \[[@CR11]\]. Among the 44 patients who received either rosuvastatin or atorvastatin, there was no statistically significant difference between both drugs in lowering the LDL-C and TC/HDL-C ratio.

Although rosuvastatin will soon be generic, and atorvastatin has been available in a generic form for several years, when the study was initiated, the cost of rosuvastatin or atorvastatin was over \$US5 per tablet. During the course of this study, our group of patients saved approximately \$US42,195 with periodic treatment compared with conventional daily dosing. Using our data, the cost savings for treating 1 million patients, at the current cash cost of 90 generic atorvastatin for \$US53 \[[@CR12]\] would be a savings of \$US197 million per year. Supported by the pharmacokinetics of these two drugs, a dosing schedule of every other day may permit effective treatment with a 50 % savings to the patient. Periodic rosuvastatin and atorvastatin dosing from once weekly to every other day has been studied and been shown to result in significant cholesterol reduction. Our study is the first to adapt a pragmatic stepwise approach, offering patient input to manage their hyperlipidemia. During the 8-year period, the patients were given the opportunity to choose a dosage regimen based on how they responded to treatment with a defined goal of TC/HDL-C ratio \<5. Using a patient-directed stepwise approach, we demonstrated sustained patient adherence of 95.7 %, which compares favorably with figures for daily dosing from the literature. Several studies have found 36--60 % of the patients were adherent to prescribed statin dosing after 12 months \[[@CR13], [@CR14]\]. Patient-directed therapy promoted an acceptable quality of life while reaching the stated lipid treatment goals in an office setting. This study adds evidence to the utility of a patient-centered approach to managing hyperlipidemia in select patients. Limitations of the study include the small cohort and the retrospective design nature. There was no cardiovascular endpoint measurement to see whether this treatment strategy was associated with favorable cardiovascular outcomes compared with daily statin dosing. Although no cardiac events occurred during the 8 years reviewed, additional comparative studies with a larger patient population are required to confirm the long-term cardioprotective effects of periodic statin dosing.
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